Attached please find herewith newspaper advertisement
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories published newspaper advertisements on May 29, 2026 disclosing its standalone and consolidated financial results for Q4 and full year ended March 31, 2026. Consolidated total income grew 13.5% year-on-year to ₹1,47,122.7 million in FY2026, compared to ₹1,29,645.2 million in FY2025. However, Q4 FY26 net profit after tax (attributable to owners) declined 22.7% to ₹2,364.6 million from ₹3,058.6 million in Q4 FY25. Full-year consolidated net profit increased 6.3% to ₹23,018.0 million from ₹21,654.8 million. Standalone revenue from continuing operations rose to ₹96,639.1 million for FY2026, up 9.6% from ₹88,134.4 million. The audit committee reviewed results on May 27, 2026, and the Board approved them on May 28, 2026, with auditors issuing an unmodified review report.
The Q4 profit decline is a near-term concern for shareholders, though strong full-year performance with 6.3% profit growth and 13.5% revenue growth indicates resilience. The company continues to deliver steady annual performance despite quarterly volatility.